Physician profile
Robert Lewenson
NPI 1235181769
$58,059.95
in general payments reported to CMS, 2019-2025
17 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $26K · 2021: $872 · 2022: $27K · 2023: $1,574 · 2024: $1,029 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $50,955.26 | 2019-2024 | Acuvue |
| Coopervision INC. | $2,233.36 | 2019-2024 | Clariti Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb Americas INC. | $1,340.74 | 2022-2023 | Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,020.04 | 2019-2021 | |
| Alcon Vision LLC | $681.56 | 2019-2025 | Total30, Clareon |
| Abb Con-Cise Optical Group LLC | $446.83 | 2019-2022 | |
| Amgen INC. | $265.44 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $241.52 | 2022-2023 | Tepezza |
| Lkc Technologies, INC. | $136.84 | 2023 | |
| Allergan, INC. | $126.82 | 2019 | |
| Astellas Pharma US INC | $125.00 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $125.00 | 2022 | |
| Dompe US, INC. | $116.61 | 2025 | Oxervate |
| Abbvie INC. | $91.67 | 2022 | |
| Alcon Research LLC | $86.86 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $59.52 | 2019 | |
| Optos, INC. | $6.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lewenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.